Highlights•Type I IFN is implicated in SLE pathogenesis by multiple lines of evidence,
including genetics and induction of SLE by IFN treatment.•Nucleic-acid sensing pathways …

Endogenous bioactive lipids are part of a complex network that modulates a plethora of
cellular and molecular processes involved in health and disease, of which inflammation …

The type I interferon pathway has been implicated in the pathogenesis of a number of
rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis …

Most cancers express tumor antigens that can be recognized by T cells of the host. The fact
that cancers become clinically evident nonetheless implies that immune escape must occur …

Our understanding of the genetic basis of systemic lupus erythematosus has progressed
rapidly in recent years. While many genetic polymorphisms have been associated with …

Objective Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus
(SLE) that exhibits familial aggregation and may progress to end‐stage renal disease …

Systemic lupus erythematosus (SLE; OMIM 152700) is a highly heterogeneous disorder,
characterized by differences in autoantibody profile, serum cytokines, and a multi-system …

Objective Interferon‐α (IFNα) is a primary pathogenic factor in systemic lupus erythematosus
(SLE), and high IFNα levels may be associated with particular clinical manifestations. The …

Type I interferons (IFNs) are a family of cytokines involved in the defense against viral
infections that play a key role in the activation of both the innate and adaptive immune …

Objective To investigate the hypothesis that proteasome inhibition may have potential in the
treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of …